Human embryonic stem cell therapies for neurodegenerative diseases

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 4, 2011, Pages 440-448

  Tomaskovic Crook, Eva ^a   Crook, Jeremy M ^b,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b O'Brien Institute   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cell therapy; Clinical compliance; Human embryonic stem cells; Neurodegenerative diseases; Pluripotent stem cells; Stem cell transplantation

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CARCINOGENICITY; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; HUMAN; IMMUNOGENICITY; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION;

EID: 79956300919     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711795564001     Document Type: Article

References (135)

1. Yu, J.; Vodyanik, M.A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J.L.; Tian, S.; Nie, J.; Jonsdottir, G.A.; Ruotti, V.; Stewart, R.; Slukvin, I.I.; Thomson, J.A. Induced pluripotent stem cell linesderived from human somatic cells. Science, 2007, 318, 1917-1920.
2. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells fromadult human fibroblasts by defined factors. Cell, 2007, 131, 861-872.
3. Park, I.H.; Zhao, R.; West, J.A.; Yabuuchi, A.; Huo, H.; Ince, T.A.; Lerou, P.H.; Lensch, M.W.; Daley, G.Q. Reprogramming of humansomatic cells to pluripotency with defined factors. Nature, 2008,451, 141-146.
4. Sah, D.W.; Ray, J.; Gage, F.H. Bipotent progenitor cell lines from the human CNS. Nat. Biotechnol., 1997, 15, 574-580.
5. Zhang, S.C.; Wernig, M.; Duncan, I.D.; Brustle, O.; Thomson, J.A. In vitro differentiation of transplantable neural precursors fromhuman embryonic stem cells. Nat. Biotechnol., 2001, 19, 1129-1133.
6. Reubinoff, B.E.; Itsykson, P.; Turetsky, T.; Pera, M.F.; Reinhartz, E.; Itzik, A.; Ben-Hur, T. Neural progenitors from humanembryonic stem cells. Nat. Biotechnol., 2001, 19, 1134-1140.
7. Carpenter, M.K.; Inokuma, M.S.; Denham, J.; Mujtaba, T.; Chiu, C.P.; Rao, M.S. Enrichment of neurons and neural precursors fromhuman embryonic stem cells. Exp. Neurol., 2001, 172, 383-397.
8. Strubing, C.; Ahnert-Hilger, G.; Shan, J.; Wiedenmann, B.; Hescheler, J.; Wobus, A.M. Differentiation of pluripotentembryonic stem cells into the neuronal lineage in vitro gives rise tomature inhibitory and excitatory neurons. Mech. Dev., 1995, 53,275-287.
9. Axell, M.Z.; Zlateva, S.; Curtis, M. A method for rapid derivationand propagation of neural progenitors from human embryonic stemcells. J. Neurosci. Methods, 2009, 184, 275-284.
10. Song, H.; Stevens, C.F.; Gage, F.H. Astroglia induce neurogenesisfrom adult neural stem cells. Nature, 2002, 417, 39-44.
11. Park, K.I.; Teng, Y.D.; Snyder, E.Y. The injured brain interactsreciprocally with neural stem cells supported by scaffolds toreconstitute lost tissue. Nat. Biotechnol., 2002, 20, 1111-1117.
12. Peerani, R.; Zandstra, P.W. Enabling stem cell therapies throughsynthetic stem cell-niche engineering. J. Clin. Invest., 2010, 120,60-70.
13. Couzin, J. Biotechnology. Celebration and concern over U.S. trialof embryonic stem cells. Science, 2009, 323, 568.
14. Zhang, Y.W.; Denham, J.; Thies, R.S. Oligodendrocyte progenitorcells derived from human embryonic stem cells expressneurotrophic factors. Stem Cells Dev., 2006, 15, 943-952.
15. Nistor, G.I.; Totoiu, M.O.; Haque, N.; Carpenter, M.K.; Keirstead, H.S. Human embryonic stem cells differentiate intooligodendrocytes in high purity and myelinate after spinal cordtransplantation. Glia, 2005, 49, 385-396.
16. Barde, Y. Caution urged in trial of stem cells to treat spinal-cordinjury. Nature, 2009, 458, 29.
17. Trounson, A. New perspectives in human stem cell therapeuticresearch. BMC Med., 2009, 7, 29.
18. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem celllines derived from human blastocysts. Science, 1998, 282, 1145-1147.
19. Amit, M.; Carpenter, M.K.; Inokuma, M.S.; Chiu, C.P.; Harris, C.P.; Waknitz, M.A.; Itskovitz-Eldor, J.; Thomson, J.A. Clonallyderived human embryonic stem cell lines maintain pluripotencyand proliferative potential for prolonged periods of culture. Dev.Biol., 2000, 227, 271-278.
20. Odorico, J.S.; Kaufman, D.S.; Thomson, J.A. Multilineagedifferentiation from human embryonic stem cell lines. Stem Cells,2001, 19, 193-204.
21. Kehat, I.; Kenyagin-Karsenti, D.; Snir, M.; Segev, H.; Amit, M.; Gepstein, A.; Livne, E.; Binah, O.; Itskovitz-Eldor, J.; Gepstein, L.Human embryonic stem cells can differentiate into myocytes withstructural and functional properties of cardiomyocytes. J. Clin.Invest., 2001, 108, 407-414.
22. Assady, S.; Maor, G.; Amit, M.; Itskovitz-Eldor, J.; Skorecki, K.L.; Tzukerman, M. Insulin production by human embryonic stem cells. Diabetes, 2001, 50, 1691-1697.
23. Bain, G.; Kitchens, D.; Yao, M.; Huettner, J.E.; Gottlieb, D.I. Embryonic stem cells express neuronal properties in vitro. Dev.Biol., 1995, 168, 342-357.
24. Itskovitz-Eldor, J.; Schuldiner, M.; Karsenti, D.; Eden, A.; Yanuka, O.; Amit, M.; Soreq, H.; Benvenisty, N. Differentiation of humanembryonic stem cells into embryoid bodies compromising the threeembryonic germ layers. Mol. Med., 2000, 6, 88-95.
25. McDonald, J.W.; Liu, X.Z.; Qu, Y.; Liu, S.; Mickey, S.K.; Turetsky, D.; Gottlieb, D.I.; Choi, D.W. Transplanted embryonicstem cells survive, differentiate and promote recovery in injured ratspinal cord. Nat. Med., 1999, 5, 1410-1412.
26. Deacon, T.; Dinsmore, J.; Costantini, L.C.; Ratliff, J.; Isacson, O. Blastula-stage stem cells can differentiate into dopaminergic andserotonergic neurons after transplantation. Exp. Neurol., 1998, 149,28-41.
27. Hu, B.Y.; Du, Z.W.; Li, X.J.; Ayala, M.; Zhang, S.C. Humanoligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects. Development, 2009,136, 1443-1452.
28. Li, X.J.; Du, Z.W.; Zarnowska, E.D.; Pankratz, M.; Hansen, L.O.; Pearce, R.A.; Zhang, S.C. Specification of motoneurons fromhuman embryonic stem cells. Nat. Biotechnol., 2005, 23, 215-221.
29. Li, X.J.; Hu, B.Y.; Jones, S.A.; Zhang, Y.S.; Lavaute, T.; Du, Z.W.; Zhang, S.C. Directed differentiation of ventral spinalprogenitors and motor neurons from human embryonic stem cellsby small molecules. Stem Cells, 2008, 26, 886-893.
30. Hu, B.Y.; Zhang, S.C. Differentiation of spinal motor neurons frompluripotent human stem cells. Nat. Protoc., 2009, 4, 1295-1304.
31. Wada, T.; Honda, M.; Minami, I.; Tooi, N.; Amagai, Y.; Nakatsuji, N.; Aiba, K. Highly efficient differentiation and enrichment ofspinal motor neurons derived from human and monkey embryonicstem cells. PLoS One, 2009, 4, e6722.
32. Karumbayaram, S.; Novitch, B.G.; Patterson, M.; Umbach, J.A.; Richter, L.; Lindgren, A.; Conway, A.E.; Clark, A.T.; Goldman, S.A.; Plath, K.; Wiedau-Pazos, M.; Kornblum, H.I.; Lowry, W.E.Directed differentiation of human-induced pluripotent stem cellsgenerates active motor neurons. Stem Cells, 2009, 27, 806-811.
33. Perrier, A.L.; Tabar, V.; Barberi, T.; Rubio, M.E.; Bruses, J.; Topf, N.; Harrison, N.L.; Studer, L. Derivation of midbrain dopamineneurons from human embryonic stem cells. Proc. Natl. Acad. Sci.USA, 2004, 101, 12543-12548.
34. Aubry, L.; Bugi, A.; Lefort, N.; Rousseau, F.; Peschanski, M.; Perrier, A.L. Striatal progenitors derived from human ES cellsmature into DARPP32 neurons in vitro and in quinolinic acidlesionedrats. Proc. Natl. Acad. Sci. USA, 2008, 105, 16707-16712.
35. Yan, Y.; Yang, D.; Zarnowska, E.D.; Du, Z.; Werbel, B.; Valliere, C.; Pearce, R.A.; Thomson, J.A.; Zhang, S.C. Directeddifferentiation of dopaminergic neuronal subtypes from humanembryonic stem cells. Stem Cells, 2005, 23, 781-790.
36. Swistowski, A.; Peng, J.; Han, Y.; Swistowska, A.M.; Rao, M.S.; Zeng, X. Xeno-free defined conditions for culture of humanembryonic stem cells, neural stem cells and dopaminergic neuronsderived from them. PLoS One, 2009, 4, e6233.
37. Heikkila, T.J.; Yla-Outinen, L.; Tanskanen, J.M.; Lappalainen, R.S.; Skottman, H.; Suuronen, R.; Mikkonen, J.E.; Hyttinen, J.A.; Narkilahti, S. Human embryonic stem cell-derived neuronal cellsform spontaneously active neuronal networks in vitro. Exp.Neurol., 2009, 218, 109-116.
38. Li, X.J.; Zhang, X.; Johnson, M.A.; Wang, Z.B.; Lavaute, T.; Zhang, S.C. Coordination of sonic hedgehog and Wnt signalingdetermines ventral and dorsal telencephalic neuron types fromhuman embryonic stem cells. Development, 2009, 136, 4055-4063.
39. Nilbratt, M.; Porras, O.; Marutle, A.; Hovatta, O.; Nordberg, A. Neurotrophic factors promote cholinergic differentiation in humanembryonic stem cell-derived neurons. J. Cell Mol. Med., 2009, 14,1476-1484.
40. Twelves, D.; Perkins, K.S.; Counsell, C. Systematic review ofincidence studies of Parkinson's disease. Mov. Disord., 2003, 18,19-31.
41. Agid, Y. Parkinson's disease: pathophysiology. Lancet, 1991, 337,1321-1324.
42. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J.Neurol. Neurosurg. Psychiatry, 2008, 79, 368-376.
43. Davie, C.A. A review of Parkinson's disease. Br. Med. Bull., 2008,86, 109-127.
44. Olanow, C.W. The scientific basis for the current treatment ofParkinson's disease. Annu. Rev. Med., 2004, 55, 41-60.
45. Lesage, S.; Brice, A. Parkinson's disease: from monogenic forms togenetic susceptibility factors. Hum. Mol. Genet., 2009, 18, R48-R59.
46. Yuan, H.; Zhang, Z.W.; Liang, L.W.; Shen, Q.; Wang, X.D.; Ren, S.M.; Ma, H.J.; Jiao, S.J.; Liu, P. Treatment strategies forParkinson's disease. Neurosci. Bull., 2010, 26, 66-76.
47. Jenner, P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord., 1998, 13(Suppl 1), 24-34.
48. Chiueh, C.C.; Andoh, T.; Lai, A.R.; Lai, E.; Krishna, G. Neuroprotective strategies in Parkinson's disease: protection againstprogressive nigral damage induced by free radicals. Neurotox. Res.,2000, 2, 293-310.
49. Umemura, A.; Jaggi, J.L.; Hurtig, H.I.; Siderowf, A.D.; Colcher, A.; Stern, M.B.; Baltuch, G.H. Deep brain stimulation formovement disorders: morbidity and mortality in 109 patients. J.Neurosurg., 2003, 98, 779-784.
50. Mendez, I.; Sanchez-Pernaute, R.; Cooper, O.; Vinuela, A.; Ferrari, D.; Björklund, L.; Dagher, A.; Isacson, O. Cell type analysis offunctional fetal dopamine cell suspension transplants in thestriatum and substantia nigra of patients with Parkinson's disease. Brain, 2005, 128, 1498-1510.
51. Kordower, J.H.; Freeman, T.B.; Snow, B.J.; Vingerhoets, F.J.; Mufson, E.J.; Sanberg, P.R.; Hauser, R.A.; Smith, D.A.; Nauert, G.M.; Perl, D.P.; Olanow, C.W. Neuropathological evidence ofgraft survival and striatal reinnervation after the transplantation offetal mesencephalic tissue in a patient with Parkinson's disease. N.Engl. J. Med., 1995, 332, 1118-1124.
52. Piccini, P.; Brooks, D.J.; Bjorklund, A.; Gunn, R.N.; Grasby, P.M.; Rimoldi, O.; Brundin, P.; Hagell, P.; Rehncrona, S.; Widner, H.; Lindvall, O. Dopamine release from nigral transplants visualized invivo in a Parkinson's patient. Nat. Neurosci., 1999, 2, 1137-1140.
53. Olanow, C.W.; Goetz, C.G.; Kordower, J.H.; Stoessl, A.J.; Sossi, V.; Brin, M.F.; Shannon, K.M.; Nauert, G.M.; Perl, D.P.; Godbold, J.; Freeman, T.B. A double-blind controlled trial of bilateral fetalnigral transplantation in Parkinson's disease. Ann. Neurol., 2003,54, 403-414.
54. Freed, C.R.; Greene, P.E.; Breeze, R.E.; Tsai, W.Y.; Du Mouchel, W.; Kao, R.; Dillon, S.; Winfield, H.; Culver, S.; Trojanowski, J.Q.; Eidelberg, D.; Fahn, S. Transplantation of embryonicdopamine neurons for severe Parkinson's disease. N. Engl. J. Med.,2001, 344, 710-719.
55. Lindvall, O.; Bjorklund, A. Cell therapy in Parkinson's disease. NeuroRx, 2004, 1, 382-393.
56. Arenas, E. Towards stem cell replacement therapies for Parkinson's disease. Biochem. Biophys. Res. Commun., 2010, 396, 152-156.
57. Kim, J.H.; Auerbach, J.M.; Rodriguez-Gomez, J.A.; Velasco, I.; Gavin, D.; Lumelsky, N.; Lee, S.H.; Nguyen, J.; Sánchez-Pernaute, R.; Bankiewicz, K.; McKay, R. Dopamine neurons derived fromembryonic stem cells function in an animal model of Parkinson'sdisease. Nature, 2002, 418, 50-56.
58. Bjorklund, L.M.; Sanchez-Pernaute, R.; Chung, S.; Andersson, T.; Chen, I.Y.; McNaught, K.S.; Brownell, A.L.; Jenkins, B.G.; Wahlestedt, C.; Kim, K.S.; Isacson, O. Embryonic stem cellsdevelop into functional dopaminergic neurons after transplantationin a Parkinson rat model. Proc. Natl. Acad. Sci. USA, 2002, 99,2344-2349.
59. Li, Z.; Leung, M.; Hopper, R.; Ellenbogen, R.; Zhang, M. Feederfreeself-renewal of human embryonic stem cells in 3D porousnatural polymer scaffolds. Biomaterials, 2010, 31, 404-412.
60. Sacchetti, P.; Sousa, K.M.; Hall, A.C.; Liste, I.; Steffensen, K.R.; Theofilopoulos, S.; Parish, C.L.; Hazenberg, C.; Richter, L.A.; Hovatta, O.; Gustafsson, J.A.; Arenas, E. Liver X receptors andoxysterols promote ventral midbrain neurogenesis in vivo and inhuman embryonic stem cells. Cell Stem Cell, 2009, 5, 409-419.
61. Vazin, T.; Becker, K.G.; Chen, J.; Spivak, C.E.; Lupica, C.R.; Zhang, Y.; Worden, L.; Freed, W.J. A novel combination offactors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. PLoS One, 2009,4, e6606.
62. Friling, S.; Andersson, E.; Thompson, L.H.; Jonsson, M.E.; Hebsgaard, J.B.; Nanou, E.; Alekseenko, Z.; Marklund, U.; Kjellander, S.; Volakakis, N.; Hovatta, O.; El Manira, A.; Björklund, A.; Perlmann, T.; Ericson, J. Efficient production ofmesencephalic dopamine neurons by Lmx1a expression inembryonic stem cells. Proc. Natl. Acad. Sci. USA, 2009, 106, 7613-7618.
63. Lee, H.S.; Bae, E.J.; Yi, S.H.; Shim, J.W.; Jo, A.Y.; Kang, J.S.; Yoon, E.H.; Rhee, Y.H.; Park, C.H.; Koh, H.C.; Kim, H.J.; Choi, H.S.; Han, J.W.; Lee, Y.S.; Kim, J.; Li, J.Y.; Brundin, P.; Lee, S.H. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neuronsexhibiting improved differentiation, function, and cell survival. Stem Cells, 2010, 28, 501-512.
64. Brederlau, A.; Correia, A.S.; Anisimov, S.V.; Elmi, M.; Paul, G.; Roybon, L.; Morizane, A.; Bergquist, F.; Riebe, I.; Nannmark, U.; Carta, M.; Hanse, E.; Takahashi, J.; Sasai, Y.; Funa, K.; Brundin, P.; Eriksson, P.S.; Li, J.Y. Transplantation of human embryonicstem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells, 2006, 24, 1433-1440.
65. Jonsson, M.E.; Ono, Y.; Bjorklund, A.; Thompson, L.H. Identification of transplantable dopamine neuron precursors atdifferent stages of midbrain neurogenesis. Exp. Neurol., 2009, 219,341-354.
66. Amariglio, N.; Hirshberg, A.; Scheithauer, B.W.; Cohen, Y.; Loewenthal, R.; Trakhtenbrot, L.; Paz, N.; Koren-Michowitz, M.; Waldman, D.; Leider-Trejo, L.; Toren, A.; Constantini, S.; Rechavi, G. Donor-derived brain tumor following neural stem celltransplantation in an ataxia telangiectasia patient. PLoS Med., 2009,6, e1000029.
67. Clarkson, E.D.; Zawada, W.M.; Bell, K.P.; Esplen, J.E.; Choi, P.K.; Heidenreich, K.A.; Freed, C.R. IGF-I and bFGF improvedopamine neuron survival and behavioral outcome in parkinsonianrats receiving cultured human fetal tissue strands. Exp. Neurol.,2001, 168, 183-191.
68. Clarkson, E.D.; Zawada, W.M.; Freed, C.R. GDNF reducesapoptosis in dopaminergic neurons in vitro. Neuroreport, 1995, 7,145-149.
69. Clarkson, E.D.; Zawada, W.M.; Freed, C.R. GDNF improvessurvival and reduces apoptosis in human embryonic dopaminergicneurons in vitro. Cell Tissue Res., 1997, 289, 207-210.
70. Knusel, B.; Michel, P.P.; Schwaber, J.S.; Hefti, F. Selective andnonselective stimulation of central cholinergic and dopaminergicdevelopment in vitro by nerve growth factor, basic fibroblastgrowth factor, epidermal growth factor, insulin and the insulin-likegrowth factors I and II. J. Neurosci., 1990, 10, 558-570.
71. Takayama, H.; Ray, J.; Raymon, H.K.; Baird, A.; Hogg, J.; Fisher, L.J.; Gage, F.H. Basic fibroblast growth factor increasesdopaminergic graft survival and function in a rat model ofParkinson's disease. Nat. Med., 1995, 1, 53-58.
72. Akerud, P.; Canals, J.M.; Snyder, E.Y.; Arenas, E. Neuroprotectionthrough delivery of glial cell line-derived neurotrophic factor byneural stem cells in a mouse model of Parkinson's disease. J.Neurosci., 2001, 21, 8108-8118.
73. Andereggen, L.; Meyer, M.; Guzman, R.; Ducray, A.D.; Widmer, H.R. Effects of GDNF pretreatment on function and survival oftransplanted fetal ventral mesencephalic cells in the 6-OHDA ratmodel of Parkinson's disease. Brain Res., 2009, 1276, 39-49.
74. Ogawa, R. The importance of adipose-derived stem cells andvascularized tissue regeneration in the field of tissuetransplantation. Curr. Stem Cell Res. Ther., 2006, 1, 13-20.
75. Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.; Björklund, A.; Widner, H.; Revesz, T.; Lindvall, O.; Brundin, P. Lewy bodies ingrafted neurons in subjects with Parkinson's disease suggest hostto-graft disease propagation. Nat. Med., 2008, 14, 501-503.
76. Ko, J.Y.; Park, C.H.; Koh, H.C.; Cho, Y.H.; Kyhm, J.H.; Kim, Y.S.; Lee, I.; Lee, Y.S.; Lee, S.H. Human embryonic stem cell-derived neural precursors as a continuous, stable, and on-demandsource for human dopamine neurons. J. Neurochem., 2007, 103,1417-1429.
77. Ko, J.Y.; Lee, H.S.; Park, C.H.; Koh, H.C.; Lee, Y.S.; Lee, S.H. Conditions for tumor-free and dopamine neuron-enriched graftsafter transplanting human ES cell-derived neural precursor cells. Mol. Ther., 2009, 17, 1761-1770.
78. Hong, S.; Kang, U.J.; Isacson, O.; Kim, K.S. Neural precursorsderived from human embryonic stem cells maintain long-termproliferation without losing the potential to differentiate into allthree neural lineages, including dopaminergic neurons. J. Neurochem., 2008, 104, 316-324.
79. Doi, A.; Park, I.H.; Wen, B.; Murakami, P.; Aryee, M.J.; Rizarry, R.; Herb, B.; Ladd-Acosta, C.; Rho, J.; Loewer, S.; Miller, J.; Schlaeger, T.; Daley, G.Q.; Feinberg, A.P. Differential methylationof tissue- and cancer-specific CpG island shores distinguisheshuman induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet., 2009, 41, 1350-1353.
80. Pick, M.; Stelzer, Y.; Bar-Nur, O.; Mayshar, Y.; Eden, A.; Benvenisty, N. Clone- and gene-specific aberrations of parentalimprinting in human induced pluripotent stem cells. Stem Cells,2009, 27, 2686-2690.
81. Chin, M.H.; Mason, M.J.; Xie, W.; Volinia, S.; Singer, M.; Peterson, C.; Ambartsumyan, G.; Aimiuwu, O.; Richter, L.; Zhang, J.; Khvorostov, I.; Ott, V.; Grunstein, M.; Lavon, N.; Benvenisty, N.; Croce, C.M.; Clark, A.T.; Baxter, T.; Pyle, A.D.; Teitell, M.A.; Pelegrini, M.; Plath, K.; Lowry, W.E. Induced pluripotent stemcells and embryonic stem cells are distinguished by geneexpression signatures. Cell Stem Cell, 2009, 5, 111-123.
82. Hu, B.Y.; Weick, J.P.; Yu, J.; Ma, L.X.; Zhang, X.Q.; Thomson, J.A.; Zhang, S.C. Neural differentiation of human inducedpluripotent stem cells follows developmental principles but withvariable potency. Proc. Natl. Acad. Sci. USA, 2010, 107, 4335-4340.
83. Wernig, M.; Zhao, J.P.; Pruszak, J.; Hedlund, E.; Fu, D.; Soldner, F.; Broccoli, V.; Constantine-Paton, M.; Isacson, O.; Jaenisch, R. Neurons derived from reprogrammed fibroblasts functionallyintegrate into the fetal brain and improve symptoms of rats withParkinson's disease. Proc. Natl. Acad. Sci. USA, 2008, 105, 5856-5861.
84. Vierbuchen, T.; Ostermeier, A.; Pang, Z.P.; Kokubu, Y.; Sudhof, T.C.; Wernig, M. Direct conversion of fibroblasts to functionalneurons by defined factors. Nature, 2010, 463, 1035-1041.
85. Whitehouse, P.J.; Price, D.L.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer disease: evidence for selective loss of cholinergicneurons in the nucleus basalis. Ann. Neurol., 1981, 10, 122-16.
86. Bartus, R.T.; Dean, R.L., 3rd; Beer, B.; Lippa, A.S. The cholinergichypothesis of geriatric memory dysfunction. Science, 1982, 217,408-414.
87. Coyle, J.T.; Price, D.L.; DeLong, M.R. Alzheimer's disease: adisorder of cortical cholinergic innervation. Science, 1983, 219,1184-1190.
88. Madeira, A.; Pommet, J.M.; Prochiantz, A.; Allinquant, B. SETprotein (TAF1beta, I2PP2A) is involved in neuronal apoptosisinduced by an amyloid precursor protein cytoplasmic subdomain. FASEB J., 2005, 19, 1905-1907.
89. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer'sdisease: progress and problems on the road to therapeutics. Science,2002, 297, 353-356.
90. Behl, C. Oxidative stress in Alzheimer's disease: implications forprevention and therapy. Subcell Biochem., 2005, 38, 65-78.
91. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerativedisease--a double-edged sword. Neuron, 2002, 35, 419-432.
92. Onyango, I.G.; Khan, S.M. Oxidative stress, mitochondrialdysfunction, and stress signaling in Alzheimer's disease. Curr.Alzheimer Res., 2006, 3, 339-349.
93. Biscaro, B.; Lindvall, O.; Hock, C.; Ekdahl, C.T.; Nitsch, R.M. Abeta immunotherapy protects morphology and survival of adultbornneurons in doubly transgenic APP/PS1 mice. J. Neurosci.,2009, 29, 14108-14119.
94. Bales, K.R.; Tzavara, E.T.; Wu, S.; Wade, M.R.; Bymaster, F.P.; Paul, S.M.; Nomikos, G.G. Cholinergic dysfunction in a mousemodel of Alzheimer disease is reversed by an anti-A beta antibody.J. Clin. Invest., 2006, 116, 825-832.
95. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.J.; Saido, T.C. Metabolicregulation of brain Abeta by neprilysin. Science, 2001, 292, 1550-1552.
96. Melchor, J.P.; Pawlak, R.; Strickland, S. The tissue plasminogenactivator-plasminogen proteolytic cascade accelerates amyloid-beta(Abeta) degradation and inhibits Abeta-induced neurodegeneration.J. Neurosci., 2003, 23, 8867-8871.
97. Mueller-Steiner, S.; Zhou, Y.; Arai, H.; Roberson, E.D.; Sun, B.; Chen, J.; Wang, X.; Yu, G.; Esposito, L.; Mucke, L.; Gan, L. Antiamyloidogenic and neuroprotective functions of cathepsin B:implications for Alzheimer's disease. Neuron, 2006, 51, 703-714.
98. Hemming, M.L.; Patterson, M.; Reske-Nielsen, C.; Lin, L.; Isacson, O.; Selkoe, D.J. Reducing amyloid plaque burden via exvivo gene delivery of an Abeta-degrading protease: a noveltherapeutic approach to Alzheimer disease. PLoS Med., 2007, 4,e262.
99. Tuszynski, M.H.; Thal, L.; U, H.S.; Pay, M.M.; Blesch, A.; Conner, J.; Vahlsing, H.L. Nerve growth factor gene therapy forAlzheimer's disease. J. Mol. Neurosci., 2002, 19, 207.
100. Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; U, H.S.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; Tong, G.; Potkin, S.G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J.H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor genetherapy for Alzheimer disease. Nat. Med., 2005, 11, 551-555.
101. Kang, U.J.; Fisher, L.J.; Joh, T.H.; O'Malley, K.L.; Gage, F.H. Regulation of dopamine production by genetically modifiedprimary fibroblasts. J. Neurosci., 1993, 13, 5203-5211.
102. Flax, J.D.; Aurora, S.; Yang, C.; Simonin, C.; Wills, A.M.; Billinghurst, L.L.; Jendoubi, M.; Sidman, R.L.; Wolfe, J.H.; Kim, S.U.; Snyder, E.Y. Engraftable human neural stem cells respond todevelopmental cues, replace neurons, and express foreign genes. Nat. Biotechnol., 1998, 16, 1033-1039.
103. Manabe, T.; Tatsumi, K.; Inoue, M.; Makinodan, M.; Yamauchi, T.; Makinodan, E.; Yokoyama, S.; Sakumura, R.; Wanaka, A.L3/Lhx8 is a pivotal factor for cholinergic differentiation of murineembryonic stem cells. Cell Death Differ., 2007, 14, 1080-1085.
104. Nagahara, A.H.; Merrill, D.A.; Coppola, G.; Tsukada, S.; Schroeder, B.E.; Shaked, G.M.; Wang, L.; Blesch, A.; Kim, A.; Conner, J.M.; Rockenstein, E.; Chao, M.V.; Koo, E.H.; Geschwind, D.; Masliah, E.; Chiba, A.A.; Tuszynski, M.H. Neuroprotectiveeffects of brain-derived neurotrophic factor in rodent and primatemodels of Alzheimer's disease. Nat. Med., 2009, 15, 331-337.
105. Meilandt, W.J.; Cisse, M.; Ho, K.; Wu, T.; Esposito, L.A.; Scearce-Levie, K.; Cheng, I.H.; Yu, G.Q.; Mucke, L. Neprilysinoverexpression inhibits plaque formation but fails to reducepathogenic Abeta oligomers and associated cognitive deficits inhuman amyloid precursor protein transgenic mice. J. Neurosci.,2009, 29, 1977-1986.
106. Tang, J.; Xu, H.; Fan, X.; Li, D.; Rancourt, D.; Zhou, G.; Li, Z.; Yang, L. Embryonic stem cell-derived neural precursor cellsimprove memory dysfunction in Abeta(1-40) injured rats. Neurosci. Res., 2008, 62, 86-96.
107. Wang, Q.; Matsumoto, Y.; Shindo, T.; Miyake, K.; Shindo, A.; Kawanishi, M.; Kawai, N.; Tamiya, T.; Nagao, S. Neural stem cellstransplantation in cortex in a mouse model of Alzheimer's disease. J. Med. Invest., 2006, 53, 61-69.
108. Moghadam, F.H.; Alaie, H.; Karbalaie, K.; Tanhaei, S.; NasrEsfahani, M.H.; Baharvand, H. Transplantation of primed orunprimed mouse embryonic stem cell-derived neural precursorcells improves cognitive function in Alzheimerian rats. Differentiation, 2009, 78, 59-68.
109. Zhao, C.; Deng, W.; Gage, F.H. Mechanisms and functionalimplications of adult neurogenesis. Cell, 2008, 132, 645-660.
110. Jin, K.; Peel, A.L.; Mao, X.O.; Xie, L.; Cottrell, B.A.; Henshall, D.C.; Greenberg, D.A. Increased hippocampal neurogenesis inAlzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 343-347.
111. Boekhoorn, K.; Joels, M.; Lucassen, P.J. Increased proliferationreflects glial and vascular-associated changes, but not neurogenesisin the presenile Alzheimer hippocampus. Neurobiol. Dis., 2006, 24,1-14.
112. Li, B.; Yamamori, H.; Tatebayashi, Y.; Shafit-Zagardo, B.; Tanimukai, H.; Chen, S.; Iqbal, K.; Grundke-Iqbal, I. Failure ofneuronal maturation in Alzheimer disease dentate gyrus. J. Neuropathol. Exp. Neurol., 2008, 67, 78-84.
113. Becker, M.; Lavie, V.; Solomon, B. Stimulation of endogenousneurogenesis by anti-EFRH immunization in a transgenic mousemodel of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2007,104, 1691-1696.
114. International Stem Cell Banking Initiative. ISCBI Consensusguidance for banking and supply of human embryonic stem celllines for research purposes. Stem Cell Rev., 2009, 5, 301-314.
115. Crook, J.M.; Hei, D.; Stacey, G. The International Stem CellBanking Initiative (ISCBI): raising standards to bank on. InvitroCell Dev. Biol. Anim., 2010, 46, 169-172.
116. Crook, J.M.; Peura, T.T.; Kravets, L.; Bosman, A.G.; Buzzard, J.J.; Horne, R.; Hentze, H.; Dunn, N.R.; Zweigerdt, R.; Chua, F.; Upshall, A.; Colman, A. The Generation of Six Clinical-GradeHuman Embryonic Stem Cell Lines. Cell Stem Cell, 2007, 1, 490-494.
117. Dickens, B.M. ISSCR Guidlines for the conduct of humanembryonic stem cell research (December 2006). Med. Law, 2008,27(1), 179-190.
118. U.S. FDA. CBER Ed., 2006a; Title 21.
119. U.S. FDA. CBER Ed., 2006b; Title 21.
120. Rajala, K.; Hakala, H.; Panula, S.; Aivio, S.; Pihlajamaki, H.; Suuronen, R.; Hovatta, O.; Skottman, H. Testing of nine differentxeno-free culture media for human embryonic stem cell cultures.Hum. Reprod., 2007, 22, 1231-1238.
121. Hwang, D.Y.; Kim, D.S.; Kim, D.W. Human ES and iPS cells ascell sources for the treatment of Parkinson's disease: Current stateand problems. J. Cell Biochem., 2009, 107, 1016-1020.
122. Fink, D.W., Ed. Human Embryonic Stem Cells: Regulatory Considerations; Elsevier: Boston, 2004.
123. Sivarajah, S.; Raj, G.S.; Mathews, A.J.; Sahib, N.B.; Hwang, W.S.; Crook, J.M. The generation of GLP-grade human embryonic stemcell banks from four clinical-grade cell lines for preclinicalresearch. Invitro Cell Dev. Biol. Anim., 2010, 46, 210-216.
124. Cooke, M.J.; Stojkovic, M.; Przyborski, S.A. Growth of teratomasderived from human pluripotent stem cells is influenced by thegraft site. Stem Cells Dev., 2006, 15, 254-259.
125. Hentze, H.; Soong, P.L.; Wang, S.T.; Phillips, B.W.; Putti, T.C.; Dunn, N.R. Teratoma formation by human embryonic stem cells:Evaluation of essential parameters for future safety studies. Stem Cell Res, 2009, 2(3), 198-210.
126. Roy, N.S.; Cleren, C.; Singh, S.K.; Yang, L.; Beal, M.F.; Goldman, S.A. Functional engraftment of human ES cell-deriveddopaminergic neurons enriched by coculture with telomeraseimmortalizedmidbrain astrocytes. Nat. Med., 2006, 12, 1259-1268.
127. Yang, D.; Zhang, Z.J.; Oldenburg, M.; Ayala, M.; Zhang, S.C. Human embryonic stem cell-derived dopaminergic neurons reversefunctional deficit in parkinsonian rats. Stem Cells, 2008, 26, 55-63.
128. Nguyen, M.D.; Julien, J.P.; Rivest, S. Innate immunity: the missinglink in neuroprotection and neurodegeneration? Nat. Rev.Neurosci., 2002, 3, 216-227.
129. Krystkowiak, P.; Gaura, V.; Labalette, M.; Rialland, A.; Remy, P.; Peschanski, M.; Bachoud-Lévi, A.C. Alloimmunisation to donorantigens and immune rejection following foetal neural grafts to thebrain in patients with Huntington's disease. PLoS One, 2007, 2,e166.
130. Swijnenburg, R.J.; Schrepfer, S.; Govaert, J.A.; Cao, F.; Ransohoff, K.; Sheikh, A.Y.; Haddad, M.; Connolly, A.J.; Davis, M.M.; Robbins, R.C.; Wu, J.C. Immunosuppressive therapy mitigatesimmunological rejection of human embryonic stem cell xenografts.Proc. Natl. Acad. Sci. USA, 2008, 105, 12991-12996.
131. Simard, A.R.; Soulet, D.; Gowing, G.; Julien, J.P.; Rivest, S. Bonemarrow-derived microglia play a critical role in restricting senileplaque formation in Alzheimer's disease. Neuron, 2006, 49, 489-502.
132. Schwartz, M.; Moalem, G. Beneficial immune activity after CNSinjury: prospects for vaccination. J. Neuroimmunol., 2001, 113,185-192.
133. Butovsky, O.; Kunis, G.; Koronyo-Hamaoui, M.; Schwartz, M. Selective ablation of bone marrow-derived dendritic cells increasesamyloid plaques in a mouse Alzheimer's disease model. Eur. J.Neurosci., 2007, 26, 413-416.
134. Kulbatski, I. Stem/Precursor Cell-Based CNS Therapy: The Importance of Circumventing Immune Suppression byTransplanting Autologous Cells. Stem Cell Rev, 2010, 6(3), 405-410.
135. Drukker, M.; Benvenisty, N. The immunogenicity of humanembryonic stem-derived cells. Trends Biotechnol., 2004, 22, 136-141.